- Home
- AUID vs MAIA Comparison
AUID vs MAIA Comparison
Compare AUID & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- MAIA
- Stock Information
- Founded
- AUID 2009
- MAIA 2018
- Country
- AUID United States
- MAIA United States
- Employees
- AUID N/A
- MAIA N/A
- Industry
- AUID Computer Software: Prepackaged Software
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- AUID Technology
- MAIA Health Care
- Exchange
- AUID Nasdaq
- MAIA Nasdaq
- Market Cap
- AUID 47.3M
- MAIA 56.3M
- IPO Year
- AUID N/A
- MAIA 2022
- Fundamental
- Price
- AUID $2.88
- MAIA $1.84
- Analyst Decision
- AUID
- MAIA
- Analyst Count
- AUID 0
- MAIA 0
- Target Price
- AUID N/A
- MAIA N/A
- AVG Volume (30 Days)
- AUID 180.2K
- MAIA 636.1K
- Earning Date
- AUID 11-06-2025
- MAIA 11-11-2025
- Dividend Yield
- AUID N/A
- MAIA N/A
- EPS Growth
- AUID N/A
- MAIA N/A
- EPS
- AUID N/A
- MAIA N/A
- Revenue
- AUID $2,189,524.00
- MAIA N/A
- Revenue This Year
- AUID N/A
- MAIA N/A
- Revenue Next Year
- AUID N/A
- MAIA N/A
- P/E Ratio
- AUID N/A
- MAIA N/A
- Revenue Growth
- AUID 295.86
- MAIA N/A
- 52 Week Low
- AUID $2.20
- MAIA $1.40
- 52 Week High
- AUID $9.58
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- AUID 37.63
- MAIA 64.38
- Support Level
- AUID $2.70
- MAIA $1.65
- Resistance Level
- AUID $3.00
- MAIA $1.88
- Average True Range (ATR)
- AUID 0.39
- MAIA 0.09
- MACD
- AUID 0.01
- MAIA 0.03
- Stochastic Oscillator
- AUID 35.50
- MAIA 73.33
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.